NCT00054496Unknown2 期
Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 73
- 试验地点
- 2
- 主要终点
- Response rate
研究概览
简要总结
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.
详细描述
OBJECTIVES:
- Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib.
- Determine the progression-free and overall survival of patients treated with this drug.
OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 73 patients will be accrued for this study.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Response rate
次要结局
- Overall survival
- Efficacy of erlotinib in inhibiting epidermal growth factor receptor (EGFR) signaling
- Efficacy of tumor EGFR amplification in predicting response to treatment
- Progression-free survival
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic CancerPancreatic CancerNCT00470535Roswell Park Cancer Institute18
已完成
2 期
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder CancerBladder CancerNCT00380029UNC Lineberger Comprehensive Cancer Center27
已完成
2 期
Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal CancerEsophageal CancerNCT00524121Roswell Park Cancer Institute22
已完成
2 期
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerLung CancerNCT00547105University of Texas Southwestern Medical Center24
终止
2 期
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaAdult Brain TumorsNCT00387894Michael Prados6